Previous 10 | Next 10 |
Mersana Therapeutics (NASDAQ: MRSN ) launches a public offering of 5M shares of common stock. More news on: Mersana Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
Gainers: Hertz Global (NYSE: HTZ ) +104% . More news on: Hertz Global Holdings, Inc., Euroseas Ltd., Mersana Therapeutics, Inc., Stocks on the move, , Read more ...
Mersana Therapeutics (NASDAQ: MRSN ) +42% as XMT-1536 shows positive action in ovarian cancer. More news on: Mersana Therapeutics, Inc., Phunware, Inc., Luckin Coffee Inc., Stocks on the move, , Read more ...
Mersana Therapeutics (NASDAQ: MRSN ) announces positive preliminary data from the expansion portion of a Phase 1 clinical trial evaluating antibody-drug conjugate (ADC) XMT-1536 in patients with platinum-resistant ovarian cancer or treatment-experienced non-small cell lung (NSCLC) adenoc...
- Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer - Data continue to support a NaPi2b biomarker-based patient selection strategy - Generally well-tolerated with no new safet...
The difference between greed and ambition is a greedy person desires things he isn't prepared to work for. ”― Habeeb Akande Today, we take our first look at a biotech company that just came public two years ago. Like so many in this space, the shares sell significantly und...
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today annou...
CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced ...
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today annou...
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced ...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...